BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
52.00
-0.57 (-1.08%)
Aug 29, 2025, 10:57 AM - Market open
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$323,030
Profits / Employee
-$1,063,582
Market Cap
9.94B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 730 | 174 | 31.29% |
Dec 31, 2023 | 556 | 160 | 40.40% |
Dec 31, 2022 | 396 | -182 | -31.49% |
Dec 31, 2021 | 578 | 182 | 45.96% |
Dec 31, 2020 | 396 | 148 | 59.68% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BBIO News
- 2 days ago - BridgeBio to Participate in September Investor Conferences - GlobeNewsWire
- 4 days ago - BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 - GlobeNewsWire
- 20 days ago - BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 5 weeks ago - Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - GlobeNewsWire
- 5 weeks ago - BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - GlobeNewsWire
- 2 months ago - BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - GlobeNewsWire